Chembio Diagnostics, Inc. (CEMI.OB) announced that the Pall Corporation informed Chembio that patented Dual Path Platform point-of-care test system has achieved the performance objectives of the feasibility study entered into by the companies in July 2007.
The DPP technology uses two separate and distinct membrane strips; one for the sample migration, and one for the test reagents and labeling system. This unique design allows for complete and independent control and management of the sample flow. These key technological features enable the DPP immunoassay to demonstrate improved detectability, sensitivity and specificity compared to other methods.
Bob Aromando, Chembio Senior Vice, stated, “This successful feasibility study demonstrates the significant performance advantages of DPP(TM) and further defines the value proposition our technology can provide to partners.” Chembio’s Chairman and President, Lawrence A. Siebert, commented, “I am most encouraged by our progress in several collaborations related to our DPP(TM) technology, including with Pall, as I believe they will result in new sources of revenues for Chembio. When combined with anticipated continued sales and gross margin increases from our current base of HIV and other rapid tests, we should make substantial progress toward profitability.”
Let us hear your thoughts below:
